BIVI - BioVie continues hot streak following Alzheimer's data; up 47%
- BioVie ( NASDAQ: BIVI ), which has been on a tear since releasing additional data from a Phase 2 trial for its Alzheimer's candidate NE3107 on Tuesday, is closed up 54% Wednesday.
- The stock is up ~76% since Monday's close.
- An analysis of blood samples showed a potential impact on biomarkers of aging-related diseases associated with the candidate.
- Oppenheimer's Jay Olson increased his probability of success for NE3107 to 60% for Alzheimer's and 30% for Parkinson's.
- He also raised his price target to $12 from $9.
For further details see:
BioVie continues hot streak following Alzheimer's data; up 47%